Alkane Resources has two main assets in Central West New South Wales: the Tomingley gold mine, where recent exploration has increased the mine life by at least eight years, from FY23 to FY31, and its Boda prospect at Northern Molong, which is shaping up to be a tier 1 alkalic porphyry district.
More Alkane Resources content >Investment summary
Alkane exceeded the upper end of its guidance range in FY22 by 11% at an all-in sustaining cost (AISC) of A$1,460/oz (cf guidance of A$1,500–1,650/oz). Exploration at San Antonio and Roswell has already led to an increase in Tomingley’s life from CY23 until CY31 at production levels up to 115koz pa and AISC down to A$1,350–1,450/oz. Subsequent exploration has increased the Roswell resource by 37% as well as delineating a maiden resource of 5.2Moz Au or 10.1Moz AuE at Boda.
Y/E Jun |
Revenue (A$m) |
EBITDA (A$m) |
PBT (A$m) |
EPS (fd) (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 72.5 | 29.4 | 20.6 | 2.48 | 32.7 | 15.7 |
| 2021A | 127.8 | 70.5 | 46.3 | 5.30 | 15.3 | 6.7 |
| 2022E | 162.3 | 73.3 | 42.4 | 1.71 | 47.4 | 3.5 |
| 2023E | 140.1 | 69.2 | 37.8 | 4.39 | 18.5 | 7.0 |
Industry outlook
Our valuation of Alkane continues to be underpinned by Tomingley (A$0.57/share). Liquid assets contribute a further A$0.06/share and Boda a further A$0.31/share. As such, we calculate that Alkane’s share price is now more than 100% covered by the value of tangible assets, with up to an additional A$0.59/share available in the form of further exploration success at the Northern Molong Porphyry Project as well as the gold price and the ever-increasing probability that the Roswell underground extension will be sanctioned.
Last updated on 12/08/2022Content on Alkane Resources
Sector |
|---|
|
Metals & mining
Access more Metals & mining content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (A$m) | 57.2 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Ian Gandel | Chairman |
| Nic Earner | MD |
| Ian Chalmers | Technical director |